Paul Sowyrda is a seasoned Biopharmaceutical leader and inventor with over 25 years of experience helping to build and lead development stage and commercial companies. He is co-founder of Novellus, Inc. which was sold to Brooklyn ImmunoTherapeutics, Inc. in July 2021, and served as its Executive Vice President. Mr. Sowyrda held previous positions as Vice President of Drug Development at CIBA, and Vice President of Development and Marketing at Dusa Pharmaceuticals, which was acquired by Sun Pharma. Mr. Sowyrda is an inventor and holds more than 15 patents, He has served on the Board of Directors for the Society of Concurrent Product Development and is a member of the American Academy of Dermatology and International Society of Dermatologic Surgery. He earned his B.S. and M.S. from the University of Notre Dame, his MBA from Babson College, and completed the MIT Sloan School of Management Senior Executives Program.